Topical 5-Fluorouracil Effervescent Powder in the Treatment of Vitiligo

Launched by AL-AZHAR UNIVERSITY · Sep 12, 2022

Keywords

ClinConnect Summary

This clinical trial is investigating a new way to deliver a medication called 5-Fluorouracil for treating vitiligo, a skin condition that causes patches of skin to lose their color. The researchers are testing a special effervescent powder that creates bubbles when mixed with water. This bubbling action helps the medication dissolve better, which may improve its effectiveness in treating vitiligo.

To be eligible for this study, participants must be at least 10 years old and have been diagnosed with stable vitiligo for at least a year, meaning their skin patches haven't changed in that time. They should not have received any other treatments for vitiligo in the six weeks before joining the study. Participants will be asked to sign a consent form and will be followed throughout the trial to see how well this new treatment works. It's important to note that people with certain conditions or who have received other vitiligo treatments may not qualify for this study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients who will be diagnosed as localized stable vitiligo.
• • Age older than 10 years
• • Stability of lesions for a duration of at least 1 year.
• • Patients who didn't receive treatment for vitiligo in the previous 6 weeks before starting the study.
• • Patients who agreed to join the study and signed written consent and continued till the end of the follow up period
• Exclusion Criteria:
• • Patients with vitiligo patches on mucous membrane,
• • Patients with Koebner phenomenon,
• • Other uncontrolled systemic illnesses
• • Patients receiving any systemic or topical treatment for vitiligo